Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 3/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4025564 | 1.00 | LMNA (0.38) | LMNAHTTSMN1; SMN2MAOBSLC6A4 | |
| SCHEMBL4023906 | 1.00 | LMNA (0.38) | LMNAHTTSMN1; SMN2MAOBSLC6A4 | |
| SCHEMBL4022096 | 1.00 | LMNA (0.38) | LMNAHTTSMN1; SMN2MAOBSLC6A4 | |
| SCHEMBL4022685 | 0.85 | LMNA (0.40) | LMNAHTTSMN1; SMN2MAOBSLC6A4 | |
| SCHEMBL4024901 | 0.85 | LMNA (0.40) | LMNAHTTSMN1; SMN2MAOBSLC6A4 | |
| SCHEMBL13720265 | 0.82 | IDO1 (0.41) | — | |
| SCHEMBL13720690 | 0.82 | IDO1 (0.41) | — | |
| SCHEMBL11138226 | 0.80 | LMNA (0.44) | LMNAHTTSMN1; SMN2MAOBSLC6A4 | |
| SCHEMBL4020346 | 0.78 | SLC6A4 (0.40) | LMNAHTTSMN1; SMN2MAOBSLC6A4 | |
| SCHEMBL4020641 | 0.78 | SLC6A4 (0.40) | LMNAHTTSMN1; SMN2MAOBSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569579-B2 | for inhibition of HIV replication and treatment of acquired immune deficiency syndrome | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-04 | — | — | US | disclosed |
| EP-1569934-B1 | CYCLOPROPYL COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20060052408-A1 | Cyclopropyl compounds as ccr5 antagonists | SMITHKLINE BEECHAM CORPORATION | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052408-A1 | Cyclopropyl compounds as ccr5 antagonists | CCR5, CCR1, CCL5 | LMNA 4506/4885HTT 4709/4885SMN1; SMN2 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.